Figure 5
sFas and sTRAIL levels in plasma and cell culture supernatants of ITP patients and healthy controls. (A) Plasma sFas did not differ significantly among groups A, B, C, and controls (P = .126). (B) sFas levels in cell culture supernatants of group A were significantly lower than those in control supernatants at day 6 and 10 (P < .0001). At day 14, sFas levels in cell culture supernatants did not differ significantly between ITP patients in group A and controls, and there were no remarkable differences among groups A, B, and C at any detecting time. (C) Plasma sTRAIL concentration was deceased in group A ITP patients compared with healthy controls (P < .0001). There were no remarkable differences among groups B, C, and controls. (D) At days 6, 10, and 14, sTRAIL concentration in cell culture supernatants of group A were remarkably lower than those in controls (P < .0001). There were no remarkable differences among groups B, C, and controls at any detecting time.

sFas and sTRAIL levels in plasma and cell culture supernatants of ITP patients and healthy controls. (A) Plasma sFas did not differ significantly among groups A, B, C, and controls (P = .126). (B) sFas levels in cell culture supernatants of group A were significantly lower than those in control supernatants at day 6 and 10 (P < .0001). At day 14, sFas levels in cell culture supernatants did not differ significantly between ITP patients in group A and controls, and there were no remarkable differences among groups A, B, and C at any detecting time. (C) Plasma sTRAIL concentration was deceased in group A ITP patients compared with healthy controls (P < .0001). There were no remarkable differences among groups B, C, and controls. (D) At days 6, 10, and 14, sTRAIL concentration in cell culture supernatants of group A were remarkably lower than those in controls (P < .0001). There were no remarkable differences among groups B, C, and controls at any detecting time.

Close Modal

or Create an Account

Close Modal
Close Modal